Related Experiment Video
Updated: Jul 14, 2026

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
Published on: February 28, 2025
Developmental exposure to terbutaline and chlorpyrifos, separately or sequentially, elicits presynaptic serotonergic
Theodore A Slotkin1, Frederic J Seidler
1Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA. t.slotkin@duke.edu
Abstract:
Developmental exposure to unrelated neurotoxicants can nevertheless converge on common final targets so as to exacerbate damage or functional deficits. We examined the effects of developmental exposure to terbutaline, a beta2-adrenergic receptor agonist used to arrest preterm labor, and chlorpyrifos, a widely used organophosphate pesticide, on serotonin (5HT) systems. Treatments were chosen to parallel periods typical of human developmental exposures, terbutaline (10 mg/kg) on postnatal days (PN) 2-5 and chlorpyrifos (5 mg/kg) on PN11-14, with assessments conducted in juvenile and adolescent stages (PN21, PN30 and PN45), comparing each agent alone as well as sequential administration of both. By itself, terbutaline produced persistent 5HT presynaptic hyperactivity as evidenced by increased 5HT turnover in brain regions containing 5HT terminal zones; this effect was similar to that seen in earlier studies with chlorpyrifos administration during the same early postnatal period. Later administration of chlorpyrifos (PN11-14) produced a transient increase in 5HT turnover during the juvenile stage, and the sequential exposure paradigm, terbutaline followed by chlorpyrifos, showed a corresponding increase in effect over either agent alone. In combination with our earlier work on 5HT receptors, these results indicate that terbutaline is a developmental neurotoxicant that targets the 5HT system, findings that lend a mechanistic underpinning to clinical indications of elevated childhood psychiatric disorders in the offspring of women treated with beta-agonist tocolytics. Equally importantly, the interaction between terbutaline and chlorpyrifos suggests that tocolytic therapy may alter the subsequent susceptibility to common environmental toxicants.
Insights
Developmental exposure to terbutaline and chlorpyrifos impacts serotonin systems. Sequential exposure to these neurotoxicants exacerbates effects, suggesting tocolytic therapy may increase susceptibility to environmental toxins.
Area of Science:
- Neuroscience
- Developmental Toxicology
- Pharmacology
Background:
- Developmental neurotoxicants can converge on common targets.
- Beta2-adrenergic agonists (terbutaline) and organophosphate pesticides (chlorpyrifos) are common exposures.
- Serotonin (5HT) systems are critical for neurodevelopment.
Purpose of the Study:
- To investigate the effects of developmental terbutaline and chlorpyrifos exposure on serotonin systems.
- To examine the impact of sequential exposure to these agents.
- To determine if terbutaline is a developmental neurotoxicant targeting the 5HT system.
Main Methods:
- Administered terbutaline (PN 2-5) and chlorpyrifos (PN 11-14) to juvenile and adolescent rodents.
- Assessed 5HT turnover in various brain regions at PN21, PN30, and PN45.
- Compared effects of single and sequential exposures.
Main Results:
- Terbutaline alone caused persistent 5HT presynaptic hyperactivity.
- Chlorpyrifos alone produced transient 5HT hyperactivity in juveniles.
- Sequential terbutaline and chlorpyrifos exposure showed additive/synergistic effects on 5HT turnover.
Conclusions:
- Terbutaline acts as a developmental neurotoxicant affecting the 5HT system.
- Tocolytic therapy with beta-agonists may be linked to childhood psychiatric disorders.
- Combined exposure suggests tocolytic therapy can increase susceptibility to environmental toxicants.
Related Concept Videos
Teratogenicity
Desensitization and Tachyphylaxis
Several...
